JP MORGAN/CALL/EDWARDS LIFESCIENCES/140/0.1/17.01.25 | Market Closed - Börse Stuttgart 09:54:50 17/05/2024 BST | ||
| 0.023 EUR | -34.29% |
|
| Current month | +9.52% | ||
| 1 month | -61.02% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 0.023 | -34.29% |
| 16/05/24 | 0.035 | +66.67% |
| 15/05/24 | 0.021 | +16.67% |
| 14/05/24 | 0.018 | -21.74% |
| 13/05/24 | 0.023 | -17.86% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 09:54 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | J.P. Morgan |
| WKN | JL7Y04 |
| ISIN | DE000JL7Y044 |
| Date issued | 14/07/2023 |
| Strike | 140 $ |
| Maturity | 17/01/2025 (243 Days) |
| Parity | 10 : 1 |
| Emission price | 0.24 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.29 € |
|---|---|
| Lowest since issue | 0.016 € |
| Spread | 0.153 € |
| Spread % | 85.00% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
89.14
USD
Average target price
95.9
USD
Spread / Average Target
+7.59%
- Stock Market
- Warrants
- Warrant
